PV Bulletin

Dental Composite Resin Devices - Premarket Notification (510(k)) Submissions Guidance

The FDA has issued new guidance for the premarket notification submissions regarding dental composite resin devices.

Primary source: Download the Final Guidance Document

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA has released a final guidance document on September 2, 2026, outlining comprehensive recommendations for device description, non-clinical and clinical performance testing, and labeling for dental composite resin devices.

Why it matters

This guidance is critical for manufacturers of dental composite resin devices as it establishes the standards and expectations for regulatory submissions, impacting compliance and market access.

Action needed

Companies preparing 510(k) submissions for dental composite resin devices must align with the recommendations specified in the new guidance, which include detailed testing and labeling criteria.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Inspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 1, 2026

Full briefing

Practical implication

Companies preparing 510(k) submissions for dental composite resin devices must align with the recommendations specified in the new guidance, which include detailed testing and labeling criteria.

The FDA's updated guidance assists industry in preparing premarket notification submissions (510(k)s) for dental composite resin devices, reflecting current review practices and aiming to facilitate consistent submission reviews.

What changed: The FDA has released a final guidance document on September 2, 2026, outlining comprehensive recommendations for device description, non-clinical and clinical performance testing, and labeling for dental composite resin devices.

Why it matters: This guidance is critical for manufacturers of dental composite resin devices as it establishes the standards and expectations for regulatory submissions, impacting compliance and market access.

Practical implication: Companies preparing 510(k) submissions for dental composite resin devices must align with the recommendations specified in the new guidance, which include detailed testing and labeling criteria.

View original source

  • Source: FDA - Regulatory Information
  • Published at source: 2026-09-01T00:00:00.000Z
  • Discovered by monitor: 2026-09-01T22:08:08.426Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Source-ingestion#Regulator-monitor#Usa#Fda.gov

Related updates for your role

publicFDA · USA · Updated Sep 1, 2026

Dental Curing Lights - Premarket Notification (510(k)) Submissions Guidance

Urgency: High

Manufacturers should align their premarket submissions for dental curing lights with the updated FDA guidance, ensuring to follow new recommendations on device description, performance testing, and labeling.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 1, 2026Translated From French

Modification of the Reference List of Similar Biological Groups as of September 1, 2026

Urgency: High

Ensure compliance with the updated reference list and adjust internal regulatory monitoring processes to align with the inclusion of new biologicals.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicANSM (France) · France · Updated Aug 31, 2026Translated From French

Online Peptides: Do Not Use, They Can Be Dangerous

Urgency: High

Increased vigilance and reporting obligations on illegal peptide products, with an emphasis on monitoring and managing safety signals pertaining to these substances.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicFDA · USA · Updated Aug 31, 2026

Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling

Monitoring

Pharmaceutical companies should prepare to assess the impact of hepatic impairment early in drug development, particularly for drugs that require pharmacokinetic assessments.

LabelingSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward